TissueLabs SA
| Private | |
| ISIN | 🆔 |
| Industry | Bioengineering |
| Founded 📆 | 02/01/2019 |
| Founder 👔 | |
Area served 🗺️ | |
Key people | |
| Products 📟 | 3D Bioprinters and Biomaterials |
| Members | |
Number of employees | ~10 |
| 🌐 Website | https://www.tissuelabs.com/ |
| 📇 Address | |
| 📞 telephone | |
TissueLabs SA
TissueLabs is a Swiss biotechnology company specializing in tissue engineering and organ biofabrication technologies.
Founded in 2019 by the physician-scientist Gabriel Liguori and engineer Emerson Moretto, the company develops a biofabrication platform that includes 3D bioprinters and tissue-specific biomaterials designed to replicate the physiological environment of human tissues. The platform is used by research laboratories worldwide for applications including drug testing, disease modeling, experimental tissue fabrication, and the potential future development of transplantable tissues.[1]
According to public statements from the company and its founder, one of TissueLabs’ long-term research objectives is to develop a bioartificial heart using patient-derived cells. In a 2021 interview, Liguori stated that clinical trials for a bioprinted heart would likely require an additional 10–15 years of research and development, citing the technology's early-stage nature.[1]
TissueLabs is headquartered in Bellinzona, in the canton of Ticino, Switzerland.[2]
History
Founding and Relocation to Switzerland
TissueLabs was founded in 2019, in Brazil, by physician-scientist Gabriel Liguori and engineer Emerson Moretto. The company’s concept drew on Liguori’s early exposure to congenital heart disease and his subsequent academic work in cardiovascular regenerative medicine, which led him to pursue tissue engineering and organ biofabrication.[1] TissueLabs emerged from the IPEN-Cietec incubator at the University of São Paulo and secured seed funding to develop its platform for lab-grown tissues and organs.[3]
Shortly after its founding, the company relocated its headquarters to Switzerland to operate in a specialized biotechnology environment.[1][4] Support from regional innovation organizations contributed to the relocation and subsequent international expansion. From its Swiss base, TissueLabs began supplying biomaterials, 3D bioprinters, and related technologies to research institutions globally.
Early Years
In its early years, TissueLabs focused on developing tools for laboratory research in tissue engineering and biofabrication. In its first year of operation, the company developed MatriXpec, a line of tissue-specific hydrogels designed to mimic the extracellular matrix of different human organs. By 2020, MatriXpec formulations had been developed for at least 15 tissue types, including myocardium, lung, liver, kidney, and cartilage, to support three-dimensional cell culture and bioprinting applications.[1]
In early 2020, during the COVID-19 pandemic, TissueLabs redirected part of its research efforts toward MatriWell[5], an in vitro platform for studying SARS-CoV-2 infection in lung tissue. The system combined a cell culture insert with lung-derived hydrogels to recreate a three-dimensional lung epithelium and was distributed to researchers studying viral effects on pulmonary cells.[3]
Alongside its biomaterials work, TissueLabs introduced hardware products for tissue engineering research. In 2020, the company launched TissueStart, an entry-level extrusion-based 3D bioprinter intended for academic and research laboratories.[6]
Growth
In 2021, TissueLabs introduced TissueRay, a masked stereolithography (MSLA)-based 3D bioprinter developed for biofabrication applications, and presented it at a Tissue Engineering and Regenerative Medicine International Society (TERMIS) meeting.[7] By late 2023, the company raised an additional funding round to support the establishment of its Swiss operations, including a biofabrication hub in Bellinzona that became operational in early 2024.[8][9][2]
In 2024, TissueLabs was selected for the Venture Leaders Biotech program, joining a cohort of Swiss biotechnology startups participating in a business development roadshow in the United States.[10] In June 2025, the company unveiled TissuePro, its most advanced bioprinter to date, positioned as a higher-capability system for laboratories seeking to scale up and address more complex tissue engineering applications.[11]
Recognitions
- 2018 – Forbes Under 30: Gabriel Liguori was selected for the Forbes Under 30 list.[1]
- 2020 – MIT Innovator Under 35 (MIT Technology Review): Gabriel Liguori was recognized as an Innovator Under 35 by the MIT Technology Review.[4]
- 2020 – Brasil Design Award: TissueStart™ product design awarded.
- 2021 – Top 100 Startups to Watch: Included in the ranking of emerging innovation-driven companies as one of the most promising startups.[12]
- 2021 – Mass Challenge Switzerland: Finalist[13]
- 2023 – PMI Future 50 Nomination: Gabriel Liguori was nominated for the PMI Global Future 50 list.[14]
- 2024 – The DeepTech Demo Day: Finalist
- 2025 – Top 100 Startups to Watch: Featured again in the 2025 edition of the Top 100 Startups to Watch.[15]
- 2025 – Global Impact Award category: Competitive pitch From São Paulo to the World: Scientific Innovation Ventures for Global Impact.
- 2025 – SciBiz Overall Winner.[16]
- 2025 – USP Innovation Challenge: 1st place in the category ≥ 7.[17]
- 2025 – OxFounder x SciBiz Pitch Competition: 2st place award.[18]
- 2025 – DeepTech of the Year Awards: 1st place in its category and 2nd overall.[19]
- Biotools Innovator – Finalist: Recognized in the international Biotools Innovator competition.[20]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 https://forbes.com.br/forbes-tech/2021/07/healthtech-brasileira-esta-no-caminho-para-viabilizar-impressao-em-3d-de-orgaos-humanos/
- ↑ 2.0 2.1 Welcome, Ticino (2022-01-07). "TissueLabs, the dream of a "bioheart" for transplants". Ticino Welcome. Retrieved 2026-02-17.
- ↑ 3.0 3.1 "Jovem brasileiro entra para a lista de inovadores do MIT com ambição de criar corações artificiais". Época Negócios (in português). 2022-08-23. Retrieved 2025-11-14.
- ↑ 4.0 4.1 https://www.researchgate.net/profile/Gabriel-Liguori#:~:text=Dr.%20Gabriel%20Liguori%20is%20the,an%20MIT%20Innovator%20Under%2035
- ↑ Seixas, Maria Luiza; Bartolomeo, Cynthia Silva; Lemes, Robertha; Nicoliche, Tiago; Okuda, Liria Hiromi; Martins, Leonardo; Ureshino, Rodrigo; Prado, Carla Maximo; Liguori, Tácia Tavares Aquinas; Liguori, Gabriel Romero; Stilhano, Roberta Sessa (2023-07-16). "Disruptive 3D in vitro models for respiratory disease investigation: A state-of-the-art approach focused on SARS-CoV-2 infection". Biomaterials and Biosystems. 11: 100082. doi:10.1016/j.bbiosy.2023.100082. ISSN 2666-5344. PMID 37534107 Check
|pmid=value (help). - ↑ P, Madeleine (2022-09-07). "#3DStartup: TissueLabs on Using Bioprinting to Make Artificial Organs". 3Dnatives. Retrieved 2026-02-17.
- ↑ Listek, Vanesa (2021-12-02). "New Masked SLA Bioprinter Revealed by TissueLabs". 3DPrint.com | Additive Manufacturing Business. Retrieved 2026-02-17.
- ↑ Listek, Vanesa (2021-02-11). "Bioprinting Startup TissueLabs Moves HQ from Brazil to Switzerland". 3DPrint.com | Additive Manufacturing Business. Retrieved 2026-02-17.
- ↑ "TissueLabs begins biofabrication activities in Bellinzona | Greater Zurich". www.greaterzuricharea.com. 2024-03-25. Retrieved 2026-02-17.
- ↑ "The platform for creating organs and tissues in the lab".
- ↑ Listek, Vanesa (2025-06-04). "TissueLabs Launches Advanced TissuePro Bioprinter for Labs Ready to Scale Up". 3DPrint.com | Additive Manufacturing Business. Retrieved 2026-02-17.
- ↑ https://www.riotimesonline.com/brazil-news/technology/brazils-100-startups-to-watch-2021/
- ↑ "MassChallenge Switzerland 2021 Winners revealed". www.startupticker.ch. Archived from the original on 2022-10-18. Retrieved 2025-12-12.
- ↑ https://en.clickpetroleoegas.com.br/Brazilian-doctor-and-nominee-for-the-future-50-of-2023-2/
- ↑ https://revistapegn.globo.com/startups-to-watch/noticia/2025/10/conheca-as-100-startups-to-watch-2025.ghtml
- ↑ "SciBiz 2025 sedia 1º USP Startup Innovation Challenge – Agência USP de Inovação". www.inovacao.usp.br. Retrieved 2025-12-12.
- ↑ "SciBiz 2025 sedia 1º USP Startup Innovation Challenge – Agência USP de Inovação". www.inovacao.usp.br. Retrieved 2025-12-12.
- ↑ "OxFounders x São Paulo". OxFounders Global. Retrieved 2025-12-12.
- ↑ Queirolo, Laura (2025-10-01). "Cor.Sync vence o Prêmio Deeptech do Ano no Deep Tech Summit". Anprotec (in português). Retrieved 2025-12-12.
- ↑ https://biotoolsinnovator.org/portfolio/?_program_year=2025
This article "TissueLabs" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:TissueLabs. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
